# Ligand Pharmaceuticals Inc. (LGND) stock analysis and sentiment Canonical page: https://synoptiv.com/stock/LGND Methodology: https://synoptiv.com/methodology Author: Synoptiv Research Engine Last analyzed: Aug 8, 2026 Ligand Pharmaceuticals Inc. (LGND) last closed at $293.15, in the upper half of its 52-week range of $137.14–$326.63. Composite market sentiment across 1 analysis is positive (+28 on a −100 to +100 scale), as of Aug 8, 2026. ## What the data says Ligand trades at $293.15, closer to the upper end of a 52-week band that runs from $137.14 to $326.63 — a range in which the high is nearly two and a half times the low. That spread describes a stock that has covered a great deal of ground over the past year rather than one that has oscillated in a narrow channel, and the current price sits within about 10% of the top of that band. At a $6.36 billion market capitalization, the shares carry a trailing price-to-earnings ratio of about 30 and a forward multiple near 24.5, so the market is paying a premium to the company's current earnings while pricing in higher earnings ahead. Price-to-book sits near 5.9. Behind those multiples is a business converting roughly 68% of revenue into profit, with revenue growing about 34% — margins consistent with a royalty and licensing model, where costs do not scale with revenue the way they do for a company manufacturing and selling its own drugs. Beta of 0.98 means the stock has historically moved close to in line with the broader market. The news flow splits between company-specific items and wider sector coverage. Company-specific items include the April 2026 acquisition of XOMA Royalty in a deal valued at over $700 million, framed around expanding the royalty portfolio, followed by a June announcement of a 2026 Investor Day in New York and a report of an insider selling 5,000 shares for $1.1 million. Several XOMA-related headlines — a preferred dividend and redemption notice, and a law-firm investigation solicitation — attach to the acquired entity rather than to Ligand's own operations. The remainder is general market commentary about healthcare and biotech names, in which Ligand appears as one of several stocks discussed rather than the subject. ## About Ligand Pharmaceuticals Inc. Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that acquires, funds, and licenses rights to medicines developed and commercialized by other companies. Rather than selling drugs itself, it earns royalties, milestone payments, and license fees as partnered programs advance. Its technologies include Captisol, a formulation agent used to improve the solubility and stability of injectable drugs, which is used in products such as Nexterone and Veklury. The portfolio spans approved therapies across several areas, among them Filspari for IgA nephropathy, Rylaze for acute lymphoblastic leukemia and lymphoblastic lymphoma, Tzield for type 1 diabetes, Kyprolis and Evomela for multiple myeloma, and the pneumococcal vaccines Vaxneuvance and Pneumosil. It also holds interests in earlier-stage partner candidates in oncology, respiratory, kidney, liver, and rare disease. The company was incorporated in 1987 and is based in Jupiter, Florida. ## Company profile - Symbol: LGND - Exchange: NASDAQ - Security type: Stock - Sector: Healthcare - Industry: Biotechnology - Composite sentiment: positive (28 on a -100 to +100 scale) ## Key statistics | Metric | Value | | --- | ---: | | Market capitalization | $6.36B | | Enterprise value | $5.65B | | Trailing P/E | 30.19 | | Forward P/E | 24.5 | | Price to book | 5.89 | | Price to sales | 21.89 | | Beta | 0.98 | | Net margin | 67.88% | | Revenue growth | 33.70% | | Earnings growth | 8.25% | | 52-week high | $326.63 | | 52-week low | $137.14 | | Average volume | 355.2K | ## Related stocks - [CRNX](https://synoptiv.com/stock/CRNX) - [LQDA](https://synoptiv.com/stock/LQDA) - [BLTE](https://synoptiv.com/stock/BLTE) - [DFTX](https://synoptiv.com/stock/DFTX) - [AMRX](https://synoptiv.com/stock/AMRX) - [MANE](https://synoptiv.com/stock/MANE) - [EWTX](https://synoptiv.com/stock/EWTX) - [INDV](https://synoptiv.com/stock/INDV) - [ELVN](https://synoptiv.com/stock/ELVN) - [GPCR](https://synoptiv.com/stock/GPCR) - [LLY](https://synoptiv.com/stock/LLY) ## Recent news - [RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $345](https://www.benzinga.com/news/26/08/61054911/rbc-capital-maintains-outperform-ligand-pharmaceuticals-raises-price-target-345) — Aug 7, 2026 - [Ligand Pharmaceuticals Inc (LGND) (Q2 2026) Earnings Call Highlights: Royalty Revenue Surges ...](https://finance.yahoo.com/healthcare/articles/ligand-pharmaceuticals-inc-lgnd-q2-231835055.html) — Aug 6, 2026 - [Ligand Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary](https://app.moby.co/home/research/tools/earningsCalendar/earnings-ligand-pharmaceuticals-incorporated-q2-2026-earnings-call-summary?utm_source=yahoo_finance&utm_medium=rss) — Aug 6, 2026 - [Ligand Pharmaceuticals Q2 Earnings Call Highlights](https://www.marketbeat.com/instant-alerts/ligand-pharmaceuticals-q2-earnings-call-highlights-2026-08-06/?utm_source=yahoofinance&utm_medium=yahoofinance) — Aug 6, 2026 - [This Biotech Dealmaker — Tied To Merck, Travere — Is In A Profit-Taking Zone](https://www.investors.com/news/technology/ligand-stock-ligand-pharmaceuticals-earnings-q2-2026/?src=A00220&yptr=yahoo) — Aug 6, 2026 - [Ligand Pharmaceuticals Incorporated (LGND) Q2 2026 Earnings Call Transcript](https://seekingalpha.com/article/4932313-ligand-pharmaceuticals-incorporated-lgnd-q2-2026-earnings-call-transcript) — Aug 6, 2026 - [HC Wainwright & Co. Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $358](https://www.benzinga.com/news/26/08/61013335/hc-wainwright-co-maintains-buy-ligand-pharmaceuticals-raises-price-target-358) — Aug 6, 2026 - [Ligand Pharmaceuticals Incorporated 2026 Q2 - Results - Earnings Call Presentation](https://seekingalpha.com/article/4932238-ligand-pharmaceuticals-incorporated-2026-q2-results-earnings-call-presentation) — Aug 6, 2026 - [Ligand Pharmaceuticals (NASDAQ:LGND) Beats Q2 EPS Estimates, Shares Flat on In-Line Revenue](https://www.chartmill.com/news/LGND/Chartmill-53126-Ligand-Pharmaceuticals-NASDAQLGND-Beats-Q2-EPS-Estimates-Shares-Flat-on-In-Line-Revenue) — Aug 6, 2026 - [Ligand: Q2 Earnings Snapshot](https://finance.yahoo.com/markets/stocks/articles/ligand-q2-earnings-snapshot-112429366.html) — Aug 6, 2026 ## Frequently asked questions ### What is the current market sentiment for LGND? As of Aug 8, 2026, Ligand Pharmaceuticals Inc. (LGND) carries positive (+28 on a −100 to +100 scale) composite sentiment. The score fuses recent news tone, analyst recommendations, technical posture, insider and congressional activity, and market attention into a single figure. The full breakdown of each component is in the report. ### How has LGND stock been performing? Ligand Pharmaceuticals Inc. last closed at $293.15, in the upper half of its 52-week range of $137.14–$326.63. ### What is LGND's market cap and valuation? Ligand Pharmaceuticals Inc. has a market capitalization of about $6.36B, a trailing P/E of 30.2. ### What sector is LGND in, and who are its competitors? Ligand Pharmaceuticals Inc. operates in the Healthcare sector, specifically Biotechnology. Comparable companies include CRNX, LQDA, BLTE, DFTX, AMRX. ### Where can I find a full analysis of LGND? The full LGND report covers the bull and bear cases, technical signals with entry, stop and target levels, complete financial statements, earnings history, insider and congressional trades, and the conditions that would invalidate the thesis. It requires a free account. ## Important information This page is generated from public market and company information. Data can be delayed, incomplete, or wrong. It is research and analysis, not financial advice. - [Methodology](https://synoptiv.com/methodology) - [Disclosures](https://synoptiv.com/disclosures) - [Full report](https://synoptiv.com/stock/LGND/v/1) (account and access required)